Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
PLoS One (2018) 13:e0202182
For the SURMOUNT-OSA indication, Tricare references the 2024 trial publication showing AHI reduction of 27-30 events per hour
Here is how it stacks up against other providers we have reviewed: Shed tirzepatide offers competitive pricing with different bundle structures Strive tirzepatide provides similar telehealth models at varying price points IVIM tirzepatide uses a different pricing model worth comparing Medvi tirzepatide positions itself in a similar price range Zealthy tirzepatide offers another mid-range option Fifty 410 tirzepatide competes in the same space Willow tirzepatide provides a different approach to pricing The price alone should never determine your choice
What's the dose in trials
US$ 28.10
US$ 21.68
US$ 22.59
US$ 23.56
